Mesoblast (MESO)
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and...
- Open
- 16.910
- High
- 17.060
- Low
- 16.600
- Prev. Close
- 17.020
- Volume
- 182.26K
- Turnover
- 3.04M
- Avg Price
- 16.705
- Bid/Ask Ratio
- --
- Amplitude
- 2.70%
- 52wk High
- 21.500
- Volume Ratio
- 0.89
- Turnover Ratio
- 0.21%
Mesoblast Analyst Rating
View moreForecast & Rating
Jul 14, 2026Price forecast
$35.00109.96%
Forecast & RatingBuy
3analysts
- Strong buy33.33%
- Buy66.67%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · 1 day ago, 12:45 PM
Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment
- benzinga_article · 1 day ago, 08:51 AM
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday
- Unusual Whales · 2 days ago, 07:37 PM
Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
- PUBT · 2 days ago, 07:35 PM
Mesoblast completes dosing in Phase 3 rexlemestrocel-L trial for chronic low back pain
- benzinga_article · Aug 14 at 07:06 AM
Swarmer Posts Downbeat Q2 Results, Joins TSS, ARS Pharmaceuticals, Globant And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
- Global Report · Aug 11 at 04:43 AM
Stop Falling for Earnings Spin: The True Survivor Game of Biotech, AI Edges, and India ETFs
